| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00 |
| filingDate |
1993-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8816151bd891f907b171d1aa0f9fe1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d62caba2a29725874f9e8b8f313424f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a7cc7398d1df5d1d705c399f0484bf4 |
| publicationDate |
1994-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H06172215-A |
| titleOfInvention |
Process for producing attenuated varicella-zoster virus vaccine |
| abstract |
(57) [Summary] (Modified) [Purpose] Varicella zoster virus (VZV, varic) A method for producing a live attenuated vaccine of ella zoster virus with an increased yield of VZV is provided. [Structure] VZV infection-susceptible cells selected from human diploid cells are cultured under a sufficiently high nutrient condition until a confluent monolayer culture is obtained, and the VZV-infected cells are infected with the highest possible infection level Multiplicity of infections and VZV-infected cultures are maintained in a hypertrophic state for approximately 22-96 hours and maximal infectious VZV products are harvested. According to this method, a cell density of about 500,000 cells / cm 2 is constantly obtained using a conventional culture vessel. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010522536-A |
| priorityDate |
1992-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |